期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 199, 期 3, 页码 371-381出版社
WILEY
DOI: 10.1111/bjh.18419
关键词
11q deletion; ataxia-telangiectasia mutated gene; CLL; diagnostic next-generation sequencing; rare germline variants; variants of uncertain significance; VUS
类别
资金
- Ministry of Health of the Czech Republic [00098892]
- Palacky University Olomouc [IGA_LF_2022_011]
Germline pathogenic ATM variants are associated with the risk and progression of chronic lymphocytic leukemia (CLL) patients. Most of these variants are pathogenic or predicted to be pathogenic, while a small number are benign. Patients with these pathogenic or predicted pathogenic ATM variants are more likely to develop the disease through gene inactivation, similar to patients with somatic ATM variants. Additionally, these variants are associated with reduced progression-free survival in CLL patients, comparable to the effects of ATM or TP53 gene disruptions.
Germline pathogenic ATM (ataxia-telangiectasia mutated) variants are associated with the risk of multiple cancers; however, genetic testing reveals a large number of ATM variants of uncertain significance (VUS). Here, we studied germline ATM variants occurring in a real-world cohort of 336 patients with chronic lymphocytic leukaemia (CLL) and public cancer whole-exome/genome-sequencing datasets (445 CLL, 75 mantle cell lymphoma, 216 metastatic breast cancer, 140 lung cancer patients). We found that two-thirds of rare germline ATM variants are pathogenic (18%-50%) or VUS-predicted pathogenic (50%-82%), depending on cancer type and reaching a prevalence of up to 8%, and one-third are VUS-predicted benign. Patients with both pathogenic and VUS-predicted pathogenic variants, all heterozygous, mostly missense, are more predisposed to biallelic ATM inactivation by acquiring deletion (del)11q than patients without these variants, similar to patients with somatic ATM variants. A functional assay of ATM activity in primary CLL cells proved that VUS-predicted pathogenic ATM variants partially reduce ATM activity and concurrent del(11q) leads to complete loss of ATM activity. The rare germline variants were associated with reduced progression-free survival in CLL on novel agents, comparable to somatic ATM or TP53 disruptions. Our results highlight the need to determine the pathogenicity of VUS in clinically relevant genes such as ATM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据